Therapeutic potential of Coprinus comatus nanogels: Antiarthritic and anti-inflammatory effects in rheumatoid arthritis models.
Gespeichert in:
| Titel: | Therapeutic potential of Coprinus comatus nanogels: Antiarthritic and anti-inflammatory effects in rheumatoid arthritis models. |
|---|---|
| Autoren: | Ratnaningtyas, Nuniek Ina1 nuniek165@yahoo.com, Husen, Fajar2 fajarhusen001@gmail.com |
| Quelle: | Veterinary World. Mar2025, Vol. 18 Issue 3, p582-597. 16p. |
| Publikationsart: | Article |
| Schlagworte: | Tumor necrosis factors, Laboratory rats, Enzyme-linked immunosorbent assay, One-way analysis of variance, Rheumatoid arthritis |
| Author-Supplied Keywords: | anti-inflammatory Coprinus comatus cytokine reduction herbal medicine nanogels rheumatoid arthritis |
| Abstract: | Background and Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation and systemic immune dysregulation. The current pharmacological treatments, primarily synthetic drugs, often present adverse effects and long-term toxicity. This study explores the therapeutic potential of Coprinus comatus nanogels as a novel herbal formulation with antiarthritic and anti-inflammatory properties in a Complete Freund's Adjuvant (CFA)-induced rat model of RA. The study aims to evaluate the efficacy of C. comatus nanogels in reducing pro-inflammatory cytokine levels, antibody production, paw edema, and arthritis indices and to assess their potential as a safer alternative to conventional RA therapies. Materials and Methods: Twenty-four male Wistar rats were randomized into six groups: Healthy control, negative control (CFA-induced without treatment), positive control (sodium diclofenac 0.012 g/mL), and three treatment groups (TG1, TG2, and TG3) receiving 250, 500, and 750 mg/kg C. comatus nanogels, respectively. Oral treatments were administered for 30 days. Pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-a], interleukin [IL]-6, IL-1ß), antibodies (immunoglobulin [Ig]G, IgE), cyclooxygenase-2 (COX-2) enzyme activity, paw edema, and arthritis indices were measured using enzyme-linked immunosorbent assay and standard methods. Statistical analyses were conducted using one-way analysis of variance. Results: The 750 mg/kg dose of C. comatus nanogels significantly reduced TNF-a (17.71%), IL-1ß (19.83%), and IgE (23.91%) levels. The 250 mg/kg dose exhibited the highest reductions in IL-6 (30.88%) and COX-2 (16.54%) levels. TGs demonstrated a 27.75% reduction in paw edema and a 45.45% reduction in arthritis indices. Key bioactive compounds contributing to these effects included flavonoids, polyphenols, triterpenoids, and ß-glucans. Conclusions: C. comatus nanogels demonstrated promising anti-inflammatory and antiarthritic properties, suggesting their potential as an alternative herbal treatment for RA. Further studies are recommended to explore the long-term safety and clinical applicability of C. comatus nanogels in human RA management. [ABSTRACT FROM AUTHOR] |
| Copyright of Veterinary World is the property of Veterinary World and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Author Affiliations: | 1Department of Biology, Faculty of Biology, Universitas Jenderal Soedirman (UNSOED), Purwokerto 53122, Central Java, Indonesia 2Department of Medical Laboratory of Technology, Bina Cipta Husada College of Health Science, Purwokerto 53144, Central Java, Indonesia |
| ISSN: | 0972-8988 |
| DOI: | 10.14202/vetworld.2025.582-597 |
| Dokumentencode: | 184358655 |
| Datenbank: | Veterinary Source |
| Abstract: | Background and Aim: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent joint inflammation and systemic immune dysregulation. The current pharmacological treatments, primarily synthetic drugs, often present adverse effects and long-term toxicity. This study explores the therapeutic potential of Coprinus comatus nanogels as a novel herbal formulation with antiarthritic and anti-inflammatory properties in a Complete Freund's Adjuvant (CFA)-induced rat model of RA. The study aims to evaluate the efficacy of C. comatus nanogels in reducing pro-inflammatory cytokine levels, antibody production, paw edema, and arthritis indices and to assess their potential as a safer alternative to conventional RA therapies. Materials and Methods: Twenty-four male Wistar rats were randomized into six groups: Healthy control, negative control (CFA-induced without treatment), positive control (sodium diclofenac 0.012 g/mL), and three treatment groups (TG1, TG2, and TG3) receiving 250, 500, and 750 mg/kg C. comatus nanogels, respectively. Oral treatments were administered for 30 days. Pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-a], interleukin [IL]-6, IL-1ß), antibodies (immunoglobulin [Ig]G, IgE), cyclooxygenase-2 (COX-2) enzyme activity, paw edema, and arthritis indices were measured using enzyme-linked immunosorbent assay and standard methods. Statistical analyses were conducted using one-way analysis of variance. Results: The 750 mg/kg dose of C. comatus nanogels significantly reduced TNF-a (17.71%), IL-1ß (19.83%), and IgE (23.91%) levels. The 250 mg/kg dose exhibited the highest reductions in IL-6 (30.88%) and COX-2 (16.54%) levels. TGs demonstrated a 27.75% reduction in paw edema and a 45.45% reduction in arthritis indices. Key bioactive compounds contributing to these effects included flavonoids, polyphenols, triterpenoids, and ß-glucans. Conclusions: C. comatus nanogels demonstrated promising anti-inflammatory and antiarthritic properties, suggesting their potential as an alternative herbal treatment for RA. Further studies are recommended to explore the long-term safety and clinical applicability of C. comatus nanogels in human RA management. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 09728988 |
| DOI: | 10.14202/vetworld.2025.582-597 |